1
|
Shang S, Li X, Wang H, Zhou Y, Pang K, Li P, Liu X, Zhang M, Li W, Li Q, Chen X. Targeted therapy of kidney disease with nanoparticle drug delivery materials. Bioact Mater 2024; 37:206-221. [PMID: 38560369 PMCID: PMC10979125 DOI: 10.1016/j.bioactmat.2024.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 03/09/2024] [Accepted: 03/10/2024] [Indexed: 04/04/2024] Open
Abstract
With the development of nanomedicine, nanomaterials have been widely used, offering specific drug delivery to target sites, minimal side effects, and significant therapeutic effects. The kidneys have filtration and reabsorption functions, with various potential target cell types and a complex structural environment, making the strategies for kidney function protection and recovery after injury complex. This also lays the foundation for the application of nanomedicine in kidney diseases. Currently, evidence in preclinical and clinical settings supports the feasibility of targeted therapy for kidney diseases using drug delivery based on nanomaterials. The prerequisite for nanomedicine in treating kidney diseases is the use of carriers with good biocompatibility, including nanoparticles, hydrogels, liposomes, micelles, dendrimer polymers, adenoviruses, lysozymes, and elastin-like polypeptides. These carriers have precise renal uptake, longer half-life, and targeted organ distribution, protecting and improving the efficacy of the drugs they carry. Additionally, attention should also be paid to the toxicity and solubility of the carriers. While the carriers mentioned above have been used in preclinical studies for targeted therapy of kidney diseases both in vivo and in vitro, extensive clinical trials are still needed to ensure the short-term and long-term effects of nano drugs in the human body. This review will discuss the advantages and limitations of nanoscale drug carrier materials in treating kidney diseases, provide a more comprehensive catalog of nanocarrier materials, and offer prospects for their drug-loading efficacy and clinical applications.
Collapse
Affiliation(s)
- Shunlai Shang
- Department of Nephrology, China-Japan Friendship Hospital, Beijing, China
| | - Xiangmeng Li
- Department of Nephrology, China-Japan Friendship Hospital, Beijing, China
- Key Laboratory of Bone Metabolism and Physiology in Chronic Kidney Disease of Hebei Province, China
- Peking Union Medical College, Beijing, China
| | - Haoran Wang
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
| | - Yena Zhou
- School of Medicine, Nankai University, Tianjin, China
| | - Keying Pang
- College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei Province, China
| | - Ping Li
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
| | - Xiaomin Liu
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
| | - Min Zhang
- Department of Nephrology, Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, China
| | - Wenge Li
- Department of Nephrology, China-Japan Friendship Hospital, Beijing, China
| | - Qinggang Li
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
| | - Xiangmei Chen
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People’s Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
| |
Collapse
|
2
|
Huang LF, Ye QR, Chen XC, Huang XR, Zhang QF, Wu CY, Liu HF, Yang C. Research Progress of Drug Delivery Systems Targeting the Kidneys. Pharmaceuticals (Basel) 2024; 17:625. [PMID: 38794195 PMCID: PMC11124227 DOI: 10.3390/ph17050625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2024] [Revised: 05/03/2024] [Accepted: 05/10/2024] [Indexed: 05/26/2024] Open
Abstract
Chronic kidney disease (CKD) affects more than 10% of the global population, and its incidence is increasing, partially due to an increase in the prevalence of disease risk factors. Acute kidney injury (AKI) is an independent risk factor for CKD and end-stage renal disease (ESRD). The pathogenic mechanisms of CKD provide several potential targets for its treatment. However, due to off-target effects, conventional drugs for CKD typically require high doses to achieve adequate therapeutic effects, leading to long-term organ toxicity. Therefore, ideal treatments that completely cure the different types of kidney disease are rarely available. Several approaches for the drug targeting of the kidneys have been explored in drug delivery system research. Nanotechnology-based drug delivery systems have multiple merits, including good biocompatibility, suitable degradability, the ability to target lesion sites, and fewer non-specific systemic effects. In this review, the development, potential, and limitations of low-molecular-weight protein-lysozymes, polymer nanomaterials, and lipid-based nanocarriers as drug delivery platforms for treating AKI and CKD are summarized.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Hua-Feng Liu
- Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China; (L.-F.H.); (Q.-R.Y.); (X.-C.C.); (X.-R.H.); (Q.-F.Z.); (C.-Y.W.)
| | - Chen Yang
- Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524001, China; (L.-F.H.); (Q.-R.Y.); (X.-C.C.); (X.-R.H.); (Q.-F.Z.); (C.-Y.W.)
| |
Collapse
|
3
|
Advanced Drug Delivery Systems for Renal Disorders. Gels 2023; 9:gels9020115. [PMID: 36826285 PMCID: PMC9956928 DOI: 10.3390/gels9020115] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 01/17/2023] [Accepted: 01/20/2023] [Indexed: 02/04/2023] Open
Abstract
Kidney disease management and treatment are currently causing a substantial global burden. The kidneys are the most important organs in the human urinary system, selectively filtering blood and metabolic waste into urine via the renal glomerulus. Based on charge and/or molecule size, the glomerular filtration apparatus acts as a barrier to therapeutic substances. Therefore, drug distribution to the kidneys is challenging, resulting in therapy failure in a variety of renal illnesses. Hence, different approaches to improve drug delivery across the glomerulus filtration barrier are being investigated. Nanotechnology in medicine has the potential to have a significant impact on human health, from illness prevention to diagnosis and treatment. Nanomaterials with various physicochemical properties, including size, charge, surface and shape, with unique biological attributes, such as low cytotoxicity, high cellular internalization and controllable biodistribution and pharmacokinetics, have demonstrated promising potential in renal therapy. Different types of nanosystems have been employed to deliver drugs to the kidneys. This review highlights the features of the nanomaterials, including the nanoparticles and corresponding hydrogels, in overcoming various barriers of drug delivery to the kidneys. The most common delivery sites and strategies of kidney-targeted drug delivery systems are also discussed.
Collapse
|
4
|
Chade AR, Bidwell GL. Novel Drug Delivery Technologies and Targets for Renal Disease. Hypertension 2022; 79:1937-1948. [PMID: 35652363 PMCID: PMC9378601 DOI: 10.1161/hypertensionaha.122.17944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The burden of acute and chronic kidney diseases to the health care system is exacerbated by the high mortality that this disease carries paired with the still limited availability of comprehensive therapies. A reason partially resides in the complexity of the kidney, with multiple potential target cell types and a complex structural environment that complicate strategies to protect and recover renal function after injury. Management of both acute and chronic renal disease, irrespective of the cause, are mainly focused on supportive treatments and renal replacement strategies when needed. Emerging preclinical evidence supports the feasibility of drug delivery technology for the kidney, and recent studies have contributed to building a robust catalog of peptides, proteins, nanoparticles, liposomes, extracellular vesicles, and other carriers that may be fused to therapeutic peptides, proteins, nucleic acids, or small molecule drugs. These fusions can display a precise renal uptake, an enhanced circulating time, and a directed intraorgan biodistribution while protecting their cargo to improve therapeutic efficacy. However, several hurdles that slow the transition towards clinical applications are still in the way, such as solubility, toxicity, and sub-optimal renal targeting. This review will discuss the feasibility and current limitations of drug delivery technologies for the treatment of renal disease, offering an update on their potential and the future directions of these promising strategies.
Collapse
Affiliation(s)
- Alejandro R. Chade
- Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS
- Department of Medicine, University of Mississippi Medical Center, Jackson, MS
- Department of Radiology, University of Mississippi Medical Center, Jackson, MS
| | - Gene L. Bidwell
- Department of Neurology, University of Mississippi Medical Center, Jackson, MS
- Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS
- Department of Pharmacology, University of Mississippi Medical Center, Jackson, MS
| |
Collapse
|
5
|
Liu D, Du Y, Jin FY, Xu XL, Du YZ. Renal Cell-Targeted Drug Delivery Strategy for Acute Kidney Injury and Chronic Kidney Disease: A Mini-Review. Mol Pharm 2021; 18:3206-3222. [PMID: 34337953 DOI: 10.1021/acs.molpharmaceut.1c00511] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), have become a global public health concern associated with high morbidity, mortality, and healthcare costs. However, at present, very few effective and specific drug therapies are available, owing to the poor therapeutic efficacy and systemic side effects. Kidney-targeted drug delivery, as a potential strategy for solving these problems, has received great attention in the fields of AKI and CKD in recent years. Here, we review the literature on renal targeted, more specifically, renal cell-targeted formulations of AKI and CKD that offered biodistribution data. First, we provide a broad overview of the unique structural characteristics and injured cells of acute and chronic injured kidneys. We then separately summarize literature examples of renal targeted formulations according to the difference of target cells and elaborate on the appropriate formulation design criteria for AKI and CKD. Finally, we propose a hypothetic strategy to improve the renal accumulation of glomerular cell-targeted formulation by escaping the uptake of the reticuloendothelial system and provide some perspectives for future studies.
Collapse
Affiliation(s)
- Di Liu
- Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, China
| | - Yan Du
- Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, China
| | - Fei-Yang Jin
- Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, China
| | - Xiao-Ling Xu
- Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, China
| | - Yong-Zhong Du
- Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, China
| |
Collapse
|
6
|
Fleischmann D, Goepferich A. General sites of nanoparticle biodistribution as a novel opportunity for nanomedicine. Eur J Pharm Biopharm 2021; 166:44-60. [PMID: 34087354 DOI: 10.1016/j.ejpb.2021.05.027] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 05/22/2021] [Accepted: 05/27/2021] [Indexed: 02/07/2023]
Abstract
The development of nanomedical devices has led to a considerable number of clinically applied nanotherapeutics. Yet, the overall poor translation of nanoparticular concepts into marketable systems has not met the initial expectations and led to increasing criticism in recent years. Most novel nano approaches thereby use highly refined formulations including a plethora of active targeting sequences, but ultimately fail to reach their target due to a generally high off-target deposition in organs such as the liver or kidney. In this context, we argue that initial nanoparticle (NP) development should not entirely become set on conventional formulation aspects. In contrast, we propose a change of focus towards a prior analysis of general sites of NP in vivo deposition and an assessment of how accumulation in these organs or tissues can be harnessed to develop therapies for site-related pathologies. We therefore give a comprehensive overview of existing nanotherapeutic targeting strategies for specific cell types within three of the usual suspects, i.e. the liver, kidney and the vascular system. We discuss the physiological surroundings and relevant pathologies of described tissues as well as the implications for NP-mediated drug delivery. Additionally, successful cell-selective NP concepts using active targeting strategies are assessed. By bringing together both (patho)physiological aspects and concepts for cell-selective NP formulations, we hope to show a novel opportunity for the development of more promising nanotherapeutic devices.
Collapse
Affiliation(s)
- Daniel Fleischmann
- Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93053 Regensburg, Germany
| | - Achim Goepferich
- Department of Pharmaceutical Technology, University of Regensburg, Universitaetsstrasse 31, 93053 Regensburg, Germany.
| |
Collapse
|
7
|
van Asbeck AH, Dieker J, Boswinkel M, van der Vlag J, Brock R. Kidney-targeted therapies: A quantitative perspective. J Control Release 2020; 328:762-775. [DOI: 10.1016/j.jconrel.2020.09.022] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Revised: 09/08/2020] [Accepted: 09/09/2020] [Indexed: 01/23/2023]
|
8
|
Chen Z, Peng H, Zhang C. Advances in kidney-targeted drug delivery systems. Int J Pharm 2020; 587:119679. [PMID: 32717283 DOI: 10.1016/j.ijpharm.2020.119679] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Revised: 06/28/2020] [Accepted: 07/18/2020] [Indexed: 12/19/2022]
Abstract
The management and treatment of kidney diseases currently have caused a huge global burden. Although the application of nanotechnology for the therapy of kidney diseases is still at an early stages, it has profound potential of development. More and more nano-based drug delivery systems provide novel solutions for the treatment of kidney diseases. This article summarizes the physiological and anatomical properties of the kidney and the biological and physicochemical characters of drug delivery systems, which affects the ability of drug to target the kidney, and highlights the prospects, opportunities, and challenges of nanotechnology in the therapy of kidney diseases.
Collapse
Affiliation(s)
- Zhong Chen
- Department of Pharmaceutics, Daqing Campus of Harbin Medical University, 1 Xinyang Rd, Daqing 163319, China
| | - Haisheng Peng
- Department of Pharmaceutics, Daqing Campus of Harbin Medical University, 1 Xinyang Rd, Daqing 163319, China.
| | - Changmei Zhang
- Department of Pharmaceutics, Daqing Campus of Harbin Medical University, 1 Xinyang Rd, Daqing 163319, China.
| |
Collapse
|
9
|
Maslanka Figueroa S, Fleischmann D, Beck S, Tauber P, Witzgall R, Schweda F, Goepferich A. Nanoparticles Mimicking Viral Cell Recognition Strategies Are Superior Transporters into Mesangial Cells. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2020; 7:1903204. [PMID: 32537398 PMCID: PMC7284201 DOI: 10.1002/advs.201903204] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Revised: 03/12/2020] [Accepted: 03/17/2020] [Indexed: 05/22/2023]
Abstract
Poor drug availability in the tissue of interest is a frequent cause of therapy failure. While nanotechnology has developed a plethora of nanocarriers for drug transport, their ability to unequivocally identify cells of interest remains moderate. Viruses are the ideal nanosized carriers as they are able to address their embedded nucleic acids with high specificity to their host cells. Here, it is reported that particles endowed with a virus-like ability to identify cells by three consecutive checks have a superior ability to recognize mesangial cells (MCs) in vivo compared to conventional nanoparticles. Mimicking the initial viral attachment followed by a stepwise target cell recognition process leads to a 5- to 15-fold higher accumulation in the kidney mesangium and extensive cell uptake compared to particles lacking one or both of the viral traits. These results highlight the relevance that the viral cell identification process has on specificity and its application on the targeting strategies of nanomaterials. More so, these findings pave the way for transporting drugs into the mesangium, a tissue that is pivotal in the development of diabetic nephropathy and for which currently no efficient pharmacotherapy exists.
Collapse
Affiliation(s)
| | - Daniel Fleischmann
- Department of Pharmaceutical TechnologyUniversity of RegensburgRegensburg93053Germany
| | - Sebastian Beck
- Department of Pharmaceutical TechnologyUniversity of RegensburgRegensburg93053Germany
| | - Philipp Tauber
- Department of Physiology IIUniversity of RegensburgRegensburg93053Germany
| | - Ralph Witzgall
- Department of Molecular and Cellular AnatomyUniversity of RegensburgRegensburg93053Germany
| | - Frank Schweda
- Department of Physiology IIUniversity of RegensburgRegensburg93053Germany
| | - Achim Goepferich
- Department of Pharmaceutical TechnologyUniversity of RegensburgRegensburg93053Germany
| |
Collapse
|
10
|
Yoshikawa N, Fumoto S, Yoshikawa K, Hu D, Okami K, Kato R, Nakashima M, Miyamoto H, Nishida K. Interaction of Lipoplex with Albumin Enhances Gene Expression in Hepatitis Mice. Pharmaceutics 2020; 12:E341. [PMID: 32290201 PMCID: PMC7238045 DOI: 10.3390/pharmaceutics12040341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Revised: 04/04/2020] [Accepted: 04/09/2020] [Indexed: 12/14/2022] Open
Abstract
Understanding the in vivo fate of lipoplex, which is composed of cationic liposomes and DNA, is an important issue toward gene therapy. In disease conditions, the fate of lipoplex might change compared with the normal condition. Here, we examined the contribution of interaction with serum components to in vivo transfection using lipoplex in hepatitis mice. Prior to administration, lipoplex was incubated with serum or albumin. In the liver, the interaction with albumin enhanced gene expression in hepatitis mice, while in the lung, the interaction with serum or albumin enhanced it. In normal mice, the interaction with albumin did not enhance hepatic and pulmonary gene expression. Furthermore, hepatic and pulmonary gene expression levels of albumin-interacted lipoplex were correlated with serum transaminases in hepatitis mice. The albumin interaction increased the hepatic accumulation of lipoplex and serum tumor necrosis factor-α level. We suggest that the interaction with albumin enhanced the inflammation level after the administration of lipoplex in hepatitis mice. Consequently, the enhancement of the inflammation level might enhance the gene expression level. Information obtained in the current study will be valuable toward future clinical application of the lipoplex.
Collapse
Affiliation(s)
- Naoki Yoshikawa
- Department of Pharmacy, University of Miyazaki Hospital, 5200 Kihara, Kiyotake-cho, Miyazaki 889-1692, Japan
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| | - Shintaro Fumoto
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| | - Keiko Yoshikawa
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| | - Die Hu
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| | - Kazuya Okami
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| | - Riku Kato
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| | - Mikiro Nakashima
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| | - Hirotaka Miyamoto
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| | - Koyo Nishida
- Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki 852-8501, Japan
| |
Collapse
|
11
|
Raval N, Kumawat A, Kalyane D, Kalia K, Tekade RK. Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities. Drug Discov Today 2020; 25:862-878. [PMID: 31981791 DOI: 10.1016/j.drudis.2020.01.008] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 11/26/2019] [Accepted: 01/15/2020] [Indexed: 12/11/2022]
Abstract
Diabetes and related complications are becoming a global encumbrance. Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD). The available therapeutic modalities related to DN do not treat DN at the molecular level, proposing further amendments in the management of DN based on the pathogenesis of DN. This manuscript discusses the concept and applications of nanomedicine for the treatment of DN that can improve renal targeting, retention and localization. This review also highlights the current issues related to targeting DN, challenges and allied opportunities toward the development of next-generation drugs and treatments for the management of DN.
Collapse
Affiliation(s)
- Nidhi Raval
- National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air Force Station, Gandhinagar 382355, Gujarat, India
| | - Akshant Kumawat
- National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air Force Station, Gandhinagar 382355, Gujarat, India
| | - Dnyaneshwar Kalyane
- National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air Force Station, Gandhinagar 382355, Gujarat, India
| | - Kiran Kalia
- National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air Force Station, Gandhinagar 382355, Gujarat, India
| | - Rakesh K Tekade
- National Institute of Pharmaceutical Education and Research (NIPER) Ahmedabad, An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp. Air Force Station, Gandhinagar 382355, Gujarat, India; Indian Institute of Technology-Jammu, Jagti, PO Nagrota, Jammu 181 221, J&K, India.
| |
Collapse
|
12
|
Liu C, Hu Y, Lin J, Fu H, Lim LY, Yuan Z. Targeting strategies for drug delivery to the kidney: From renal glomeruli to tubules. Med Res Rev 2018; 39:561-578. [DOI: 10.1002/med.21532] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2018] [Revised: 07/10/2018] [Accepted: 07/18/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Chun‐Ping Liu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - You Hu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Ju‐Chun Lin
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Hua‐Lin Fu
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| | - Lee Yong Lim
- Pharmacy, Centre for Optimization of Medicines, School of Allied Health, The University of Western AustraliaCrawley Australia
| | - Zhi‐Xiang Yuan
- Department of PharmacyCollege of Veterinary Medicine, Sichuan Agricultural UniversityChengdu China
- Key Laboratory of Animal Disease and Human Health of Sichuan ProvinceChengdu China
| |
Collapse
|
13
|
Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury. Sci Rep 2017; 7:9833. [PMID: 28852159 PMCID: PMC5575043 DOI: 10.1038/s41598-017-10490-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 08/09/2017] [Indexed: 12/11/2022] Open
Abstract
Nephrotic syndrome is a common disorder in adults and children whose etiology is largely unknown. Glucocorticoids remain the mainstay of therapy in most cases, though their mechanism of action remains poorly understood. Emerging evidence suggests that immunomodulatory therapies used in nephrotic syndrome directly target the podocytes. To study how steroids directly affect the podocytes in the treatment of proteinuria, we created a mouse model with podocyte-specific deletion of the glucocorticoid receptor. The podocyte-specific glucocorticoid receptor (GR) knockout mice had similar renal function and protein excretion compared to wild type. However, after glomerular injury induced by either LPS or nephrotoxic serum, the podocyte GR knockout mice demonstrated worsened proteinuria compared to wild type. Ultrastructural examination of podocytes confirmed more robust foot process effacement in the knockout animals. Expression of several key slit diaphragm protein was down regulated in pGR KO mice. Primary podocytes isolated from wild type and podocyte GR knockout mice showed similar actin stress fiber staining patterns in unstimulated conditions. Yet, when exposed to LPS, GR knockout podocytes demonstrated fewer stress fibers and impaired migration compared to wild type podocytes. We conclude that the podocyte glucocorticoid receptor is important for limiting proteinuria in settings of podocyte injury.
Collapse
|
14
|
Yuan ZX, Jia L, Lim LY, Lin JC, Shu G, Zhao L, Ye G, Liang XX, Ji H, Fu HL. Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes. Int J Nanomedicine 2017; 12:5673-5686. [PMID: 28848346 PMCID: PMC5557620 DOI: 10.2147/ijn.s141095] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Previously, 3,5-dipentadecyloxybenzamidine hydrochloride (TRX-20)-modified liposomes were reported to specifically target mesangial cells (MCs) in glomeruli. To further gain a better understanding of the characteristics and potential application for glomerular diseases of TRX-20-modified liposomes, we synthesized TRX-20 and prepared TRX-20-modified liposomes (TRX-LPs) with different molar ratios - 6% (6%-TRX-LP), 11% (11%-TRX-LP), and 14% (14%-TRX-LP) - of TRX-20 to total lipid in the present study. All TRX-LPs exhibited concentration-dependent toxicity against the MCs at a lipid concentration ranging from 0.01 to 1.0 mg/mL with IC50 values of 3.45, 1.13, and 0.55 mg/mL, respectively. Comparison of the cell viability of TRX-LPs indicated that high levels of TRX-20 caused severe cell mortality, with 11%-TRX-LP showing the higher cytoplasmic accumulation in the MCs. Triptolide (TP) as a model drug was first loaded into 11%-TRX-LP and the liposomes were further modified with PEG5000 (PEG-TRX-TP-LP) in an attempt to prolong their circulation in blood and enhance TP-mediated immune suppression. Due to specific binding to MCs, PEG-TRX-TP-LP undoubtedly showed better anti-inflammatory action in vitro, evidenced by the inhibition of release of nitric oxide (NO) and tumor necrosis factor-α from lipopolysaccharide-stimulated MCs, compared with free TP at the same dose. In vivo, the PEG-TRX-TP-LP effectively attenuated the symptoms of membranous nephropathic (MN) rats and improved biochemical markers including proteinuria, serum cholesterol, and albumin. Therefore, it can be concluded that the TRX-modified liposome is an effective platform to target the delivery of TP to glomeruli for the treatment of MN.
Collapse
Affiliation(s)
- Zhi-xiang Yuan
- Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan
| | - Lu Jia
- Department of Neurosurgery, Shanxi Provincial People’ Hospital, Taiyuan, China
| | - Lee Yong Lim
- Pharmacy, Centre for Optimization of Medicines, School of Allied Health, The University of Western Australia, Crawley, Australia
| | - Ju-chun Lin
- Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan
| | - Gang Shu
- Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan
| | - Ling Zhao
- Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan
| | - Gang Ye
- Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan
| | - Xiao-xia Liang
- Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan
| | - Hongming Ji
- Department of Neurosurgery, Shanxi Provincial People’ Hospital, Taiyuan, China
| | - Hua-lin Fu
- Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, Sichuan
| |
Collapse
|
15
|
Abstract
Treatment and management of kidney disease currently presents an enormous global burden, and the application of nanotechnology principles to renal disease therapy, although still at an early stage, has profound transformative potential. The increasing translation of nanomedicines to the clinic, alongside research efforts in tissue regeneration and organ-on-a-chip investigations, are likely to provide novel solutions to treat kidney diseases. Our understanding of renal anatomy and of how the biological and physico-chemical properties of nanomedicines (the combination of a nanocarrier and a drug) influence their interactions with renal tissues has improved dramatically. Tailoring of nanomedicines in terms of kidney retention and binding to key membranes and cell populations associated with renal diseases is now possible and greatly enhances their localization, tolerability, and efficacy. This Review outlines nanomedicine characteristics central to improved targeting of renal cells and highlights the prospects, challenges, and opportunities of nanotechnology-mediated therapies for renal diseases.
Collapse
|
16
|
Wang L, Li X, Shen H, Mao N, Wang H, Cui L, Cheng Y, Fan J. Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy. Sci Rep 2016; 6:30964. [PMID: 27485391 PMCID: PMC4971536 DOI: 10.1038/srep30964] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2015] [Accepted: 06/29/2016] [Indexed: 02/05/2023] Open
Abstract
Mesangial deposition of aberrantly glycosylated IgA1 (agIgA1) and its immune complexes is a key pathogenic mechanism of IgA nephropathy (IgAN). However, treatment of IgAN remains ineffective. We report here that bacteria-derived IgA proteases are capable of degrading these pathogenic agIgA1 and derived immune complexes in vitro and in vivo. By screening 14 different bacterial strains (6 species), we found that 4 bacterial IgA proteases from H. influenzae, N. gonorrhoeae and N. meningitidis exhibited high cleaving activities on serum agIgA1 and artificial galactose-depleted IgA1 in vitro and the deposited agIgA1-containing immune complexes in the mesangium of renal biopsy from IgAN patients and in a passive mouse model of IgAN in vitro. In the modified mouse model of passive IgAN with abundant in situ mesangial deposition of the agIgA-IgG immune complexes, a single intravenous delivery of IgA protease from H. influenzae was able to effectively degrade the deposited agIgA-IgG immune complexes within the glomerulus, demonstrating a therapeutic potential for IgAN. In conclusion, the bacteria-derived IgA proteases are biologically active enzymes capable of cleaving the circulating agIgA and the deposited agIgA-IgG immune complexes within the kidney of IgAN. Thus, the use of such IgA proteases may represent a novel therapy for IgAN.
Collapse
Affiliation(s)
- Li Wang
- Laboratory of Organ Fibrosis Prophylaxis and Treatment by Combine Traditional Chinese and Western Medicine, Research Center of Combine Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.,State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
| | - Xueying Li
- Department of Nephrology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China
| | - Hongchun Shen
- College of Integrated Chinese and Western Medicine, Southwest Medical University, Luzhou, Sichuan, 646000, China
| | - Nan Mao
- Department of Nephrology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610041, China
| | - Honglian Wang
- Laboratory of Organ Fibrosis Prophylaxis and Treatment by Combine Traditional Chinese and Western Medicine, Research Center of Combine Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China
| | - Luke Cui
- Department of Nephrology, The Third People's Hospital of Chengdu, Chengdu, Sichuan, 610041, China
| | - Yuan Cheng
- Department of Nephrology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518000, China
| | - Junming Fan
- State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.,Department of Nephrology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.,Department of Nephrology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China
| |
Collapse
|
17
|
Wang ZY, Zhang H, Yang Y, Xie XY, Yang YF, Li Z, Li Y, Gong W, Yu FL, Yang Z, Li MY, Mei XG. Preparation, characterization, and efficacy of thermosensitive liposomes containing paclitaxel. Drug Deliv 2015; 23:1222-31. [DOI: 10.3109/10717544.2015.1122674] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Affiliation(s)
- Zhi-Yuan Wang
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| | - Hui Zhang
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| | - Yang Yang
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| | - Xiang-Yang Xie
- Wuhan General Hospital of Guangzhou Military Command, Wuhan, China, and
| | - Yan-Fang Yang
- Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Zhiping Li
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| | - Ying Li
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
| | - Wei Gong
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| | - Fang-Lin Yu
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| | - Zhenbo Yang
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| | - Ming-Yuan Li
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| | - Xing-Guo Mei
- Beijing Institute of Pharmacology and Toxicology, Beijing, China,
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing, China,
| |
Collapse
|
18
|
Zuckerman JE, Gale A, Wu P, Ma R, Davis ME. siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA. Nucleic Acid Ther 2015; 25:53-64. [PMID: 25734248 PMCID: PMC4376487 DOI: 10.1089/nat.2014.0505] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2014] [Accepted: 01/06/2015] [Indexed: 11/12/2022] Open
Abstract
There is an urgent need for new therapies that can halt or reverse the course of chronic kidney disease with minimal side-effect burden on the patient. Small interfering RNA (siRNA) nanoparticles are new therapeutic entities in clinical development that could be useful for chronic kidney disease treatment because they combine the tissue-specific targeting properties of nanoparticles with the gene-specific silencing effects of siRNA. Recent reports have emerged demonstrating that the kidney, specifically the glomerulus, is a readily accessible site for nanoparticle targeting. Here, we explore the hypothesis that intravenously administered polycationic cyclodextrin nanoparticles containing siRNA (siRNA/CDP-NPs) can be used for delivery of siRNA to the glomerular mesangium. We demonstrate that siRNA/CDP-NPs localize to the glomerular mesangium with limited deposition in other areas of the kidney after intravenous injection. Additionally, we report that both mouse and human mesangial cells rapidly internalize siRNA/CDP-NPs in vitro and that nanoparticle uptake can be enhanced by attaching the targeting ligands mannose or transferrin to the nanoparticle surface. Lastly, we show knockdown of mesangial enhanced green fluorescent protein expression in a reporter mouse strain following iv treatment with siRNA/CDP-NPs. Altogether, these data demonstrate the feasibility of mesangial targeting using intravenously administered siRNA/CDP-NPs.
Collapse
Affiliation(s)
| | - Aaron Gale
- Chemical Engineering, California Institute of Technology, Pasadena, California
| | - Peiwen Wu
- Department of Integrative Physiology and Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, Texas
| | - Rong Ma
- Department of Integrative Physiology and Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, Texas
| | - Mark E. Davis
- Chemical Engineering, California Institute of Technology, Pasadena, California
| |
Collapse
|
19
|
Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant. Eur J Pharm Biopharm 2014; 88:283-9. [PMID: 24993306 DOI: 10.1016/j.ejpb.2014.06.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2014] [Revised: 06/10/2014] [Accepted: 06/23/2014] [Indexed: 11/22/2022]
Abstract
Sepantronium bromide (YM155) exhibits time-dependent antitumor activity, although the plasma half-life of YM155 after a bolus intravenous (i.v.) administration is very short. Therefore, greater antitumor efficacy is obtained by continuous infusion than by bolus i.v. administration. In the present study, we attempted to liposomalize YM155 to obtain a longer circulation time than that achieved by bolus i.v. administration and yet retain sufficient antitumor activity. Encapsulation of YM155 in polyethylene glycol-coated liposomes extended the half-life of the drug, and high tumor accumulation of the drug was observed. Bolus i.v. administration of liposomal YM155 by a weekly administration regimen showed antitumor activity comparable to that obtained by the continuous infusion without severe toxicity in a murine xenograft model. Therefore, this liposomal formulation can be a new dosage form of YM155 that achieves sufficient efficacy and safety and is a more convenient administration regimen for users. It should be noted that liposomal YM155 showed unexpectedly high accumulation in the kidneys. This is a specific finding for liposomal YM155, offering important information for the consideration of the potential toxicity of liposomal YM155.
Collapse
|
20
|
Zuckerman JE, Davis ME. Targeting therapeutics to the glomerulus with nanoparticles. Adv Chronic Kidney Dis 2013; 20:500-7. [PMID: 24206602 DOI: 10.1053/j.ackd.2013.06.003] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Revised: 06/07/2013] [Accepted: 06/07/2013] [Indexed: 12/19/2022]
Abstract
Nanoparticles are an enabling technology for the creation of tissue-/cell-specific therapeutics that have been investigated extensively as targeted therapeutics for cancer. The kidney, specifically the glomerulus, is another accessible site for nanoparticle delivery that has been relatively overlooked as a target organ. Given the medical need for the development of more potent, kidney-targeted therapies, the use of nanoparticle-based therapeutics may be one such solution to this problem. Here, we review the literature on nanoparticle targeting of the glomerulus. Specifically, we provide a broad overview of nanoparticle-based therapeutics and how the unique structural characteristics of the glomerulus allow for selective, nanoparticle targeting of this area of the kidney. We then summarize literature examples of nanoparticle delivery to the glomerulus and elaborate on the appropriate nanoparticle design criteria for glomerular targeting. Finally, we discuss the behavior of nanoparticles in animal models of diseased glomeruli and review examples of nanoparticle therapeutic approaches that have shown promise in animal models of glomerulonephritic disease.
Collapse
|
21
|
Wang X, Lin Y, Zeng Y, Sun X, Gong T, Zhang Z. Effects of mycophenolic acid–glucosamine conjugates on the base of kidney targeted drug delivery. Int J Pharm 2013; 456:223-34. [DOI: 10.1016/j.ijpharm.2013.07.064] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Revised: 07/04/2013] [Accepted: 07/21/2013] [Indexed: 10/26/2022]
|
22
|
Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: A possible mechanism and the potential for clinical application. Int J Pharm 2012; 438:176-83. [DOI: 10.1016/j.ijpharm.2012.08.030] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2012] [Revised: 07/14/2012] [Accepted: 08/18/2012] [Indexed: 12/11/2022]
|
23
|
Kato M, Hattori Y, Kubo M, Maitani Y. Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. Int J Pharm 2011; 423:428-34. [PMID: 22197775 DOI: 10.1016/j.ijpharm.2011.12.015] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2011] [Revised: 10/21/2011] [Accepted: 12/05/2011] [Indexed: 11/18/2022]
Abstract
Elevated interstitial fluid pressure (IFP) in a tumor is a barrier to tumor accumulation of systemic delivery of nanocarriers. In this study, we investigated whether intravenous injection of type I collagenase (collagenase-1) reduced IFP in tumors and increased the accumulation and gene expression of cationic liposome/plasmid DNA complex (lipoplex) in tumors after intravenous injection into mice bearing mouse lung carcinoma LLC tumors. Collagenase-1 reduced the amount of type I collagen in the tumor, and significantly decreased IFP by 65% at 1h after injection. Therefore, collagenase-1 induced 1.5-fold higher accumulation and 2-fold higher gene expression of lipoplex in tumors after intravenous injection. These findings indicated that intravenous injection of collagenase-1 improved the accumulation of lipoplex by decreasing IFP in tumors. These results support the potential use of collagen digestion as a strategy to improve systemic gene delivery into tumors.
Collapse
Affiliation(s)
- Mako Kato
- Institute of Medicinal Chemistry, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo 142-8501, Japan
| | | | | | | |
Collapse
|
24
|
Bagavant H, Kalantarinia K, Scindia Y, Deshmukh U. Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice. Am J Kidney Dis 2011; 57:498-507. [PMID: 21239097 DOI: 10.1053/j.ajkd.2010.10.052] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2010] [Accepted: 10/11/2010] [Indexed: 11/11/2022]
Abstract
Systemic lupus erythematosus is a chronic autoimmune disease frequently affecting the kidney. Renal involvement is characterized by glomerular immune complex deposits and proliferative glomerulonephritis progressing to glomerulosclerosis and kidney failure. The development of systemic lupus erythematosus is regulated genetically, and lupus susceptibility genes have been linked to immune hyper-responsiveness and loss of immune regulation. In addition to the systemic immune defects, recent studies in animal models show that susceptibility to lupus nephritis is influenced by intrinsic renal factors. Thus, renal cell responses to immune-mediated glomerular injury determine disease outcome. This supports the idea that future treatments for lupus nephritis need to focus on regulating end-organ responses. The feasibility of this approach has been shown in animal models of kidney disease. For more than 50 years, the emphasis in management of lupus nephritis has been suppression of autoimmune responses and systemic control of inflammation. This review describes recently developed targeted drug delivery technologies and potential targets that can regulate glomerular cell responses, offering a novel therapeutic approach for lupus nephritis.
Collapse
Affiliation(s)
- Harini Bagavant
- Division of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
| | | | | | | |
Collapse
|
25
|
Scindia YM, Deshmukh US, Bagavant H. Mesangial pathology in glomerular disease: targets for therapeutic intervention. Adv Drug Deliv Rev 2010; 62:1337-43. [PMID: 20828589 DOI: 10.1016/j.addr.2010.08.011] [Citation(s) in RCA: 94] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2010] [Revised: 07/13/2010] [Accepted: 08/31/2010] [Indexed: 12/17/2022]
Abstract
The glomerulus is the filtration unit of the kidney. Disruption of glomerular function may be caused by primary glomerular pathology or secondary to systemic diseases. The mesangial, endothelial and epithelial cells of the glomerulus are involved in most pathologic processes. Animal models provide an understanding of the molecular basis of glomerular disease. These studies show that mesangial cells are critical players in the initiation and progression of disease. Therefore, modulation of mesangial cell responses offers a novel therapeutic approach. The complex architecture of the kidney, specifically the renal glomerulus, makes targeted drug delivery especially challenging. Targeted delivery of therapeutic agents reduces dose of administration and minimises unwanted side effects caused by toxicity to other tissues. The currently available modalities demonstrating the feasibility of mesangial cell targeting are discussed.
Collapse
Affiliation(s)
- Yogesh M Scindia
- Department of Medicine, University of Virginia, Charlottesville, 22908, USA
| | | | | |
Collapse
|
26
|
Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J Control Release 2009; 142:167-73. [PMID: 19861140 DOI: 10.1016/j.jconrel.2009.10.020] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2009] [Revised: 09/27/2009] [Accepted: 10/19/2009] [Indexed: 11/22/2022]
Abstract
Recently, we designed a PEG-coated cationic liposome to achieve dual targeting delivery of l-OHP to both tumor endothelial cells and tumor cells in a solid tumor. The targeted liposomal l-OHP formulation showed an efficient antitumor activity in a murine tumor model after three sequential liposomal l-OHP injections. This led us to assume that prior dosing with liposomes might enhance the intra-tumoral accumulation of a subsequent dose, and hence improve the therapeutic efficacy of entrapped l-OHP. The present study shows that while a single liposomal l-OHP injection does not enhance tumor accumulation of subsequent test-PEG-coated cationic liposomes, two sequential injections of liposomal l-OHP do. Cumulative cytotoxic effects of l-OHP delivered by PEG-coated cationic liposomes led to deep diffusion of a subsequent dose of liposomal l-OHP in solid tumor presumably as a result of the enlarged intra-tumoral interstitial space. Our study suggests that sequential injections of a targeted liposomal anticancer drug is of significant clinical and practical importance in enhancing the delivery of adequate quantities of anticancer agents into intractable solid tumors, and thereby may achieve a significant anticancer efficacy.
Collapse
|
27
|
Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 2009; 137:8-14. [DOI: 10.1016/j.jconrel.2009.02.023] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2009] [Revised: 02/23/2009] [Accepted: 02/27/2009] [Indexed: 11/23/2022]
|
28
|
Ghonaim HM, Ahmed OAA, Pourzand C, Blagbrough IS. Varying the chain length in N4,N9-diacyl spermines: non-viral lipopolyamine vectors for efficient plasmid DNA formulation. Mol Pharm 2009; 5:1111-21. [PMID: 19434924 DOI: 10.1021/mp800062j] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The aims of this work are to study the effect of varying the chain length in synthesized N4,N9-diacyl spermines on DNA condensation and then to compare their transfection efficiencies in cell lines. The five novel N4,N9-diacyl lipopolyamines: N4,N9-[didecanoyl, dilauroyl, dimyristoyl, dimyristoleoyl, and dipalmitoyl]-1,12-diamino-4,9-diazadodecane were synthesized from the naturally occurring polyamine spermine. The abilities of these novel compounds to condense DNA and to form nanoparticles were studied using ethidium bromide fluorescence quenching and nanoparticle characterization techniques. Transfection efficiency was studied in FEK4 primary skin cells and in an immortalized cancer cell line (HtTA), and compared with a saturated (distearoyl) analogue and also with the non-liposomal transfection formulation Lipogen, N4,N9-dioleoyl-1,12-diamino-4,9-diazadodecane. By incorporating two aliphatic chains and changing their length in a stepwise manner, we show efficient circular plasmid DNA (pEGFP) formulation and transfection of primary skin and cancer cell lines. Two C14 chains (both saturated or both cis-monounsaturated) were efficient transfecting agents, even in the presence of serum, but they were too toxic. N4,N9-Dioleoyl spermine efficiently condenses pDNA and achieves the highest transfection levels with the highest cell viability among the studied lipopolyamines in cultured cells even in the presence of serum.
Collapse
Affiliation(s)
- Hassan M Ghonaim
- Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
| | | | | | | |
Collapse
|
29
|
Sarembock IJ. From systemic shotgun to site-specific nanoparticle-targeted delivery: a new paradigm for drug delivery. Arterioscler Thromb Vasc Biol 2008; 28:1879-81. [PMID: 18946050 DOI: 10.1161/atvbaha.108.175190] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
MESH Headings
- Angioplasty, Balloon/adverse effects
- Angioplasty, Balloon/instrumentation
- Animals
- Anti-Inflammatory Agents/administration & dosage
- Anti-Inflammatory Agents/chemistry
- Anti-Inflammatory Agents/pharmacology
- Atherosclerosis/drug therapy
- Atherosclerosis/metabolism
- Atherosclerosis/pathology
- Atherosclerosis/therapy
- Benzamidines/chemistry
- Cell Proliferation/drug effects
- Constriction, Pathologic
- Disease Models, Animal
- Fatty Acids/chemistry
- Humans
- Iliac Artery/drug effects
- Iliac Artery/injuries
- Injections, Intravenous
- Liposomes
- Metals
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/injuries
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Nanoparticles
- Prednisolone/administration & dosage
- Prednisolone/chemistry
- Prednisolone/pharmacokinetics
- Prosthesis Design
- Secondary Prevention
- Stents
Collapse
|
30
|
Joner M, Morimoto K, Kasukawa H, Steigerwald K, Merl S, Nakazawa G, John MC, Finn AV, Acampado E, Kolodgie FD, Gold HK, Virmani R. Site-Specific Targeting of Nanoparticle Prednisolone Reduces In-Stent Restenosis in a Rabbit Model of Established Atheroma. Arterioscler Thromb Vasc Biol 2008; 28:1960-6. [DOI: 10.1161/atvbaha.108.170662] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Michael Joner
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Katsumi Morimoto
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Hiroaki Kasukawa
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Kristin Steigerwald
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Sabine Merl
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Gaku Nakazawa
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Michael C. John
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Aloke V. Finn
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Eduardo Acampado
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Frank D. Kolodgie
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Herman K. Gold
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| | - Renu Virmani
- From Deutsches Herzzentrum Muenchen und 1. Medizinische Klinik, Klinikum rechts der Isar (M.L., K.S., S.M.), Muenchen, Germany; CVPath Insitute Inc (G.N., E.A., F.D.K., R.V.), Gaithersburg, Md; Cardiac Unit (M.C.J., A.V.F., H.K.G.), Department of Internal Medicine, Massachusetts General Hospital, Boston, Mass; Research and Development Center, Terumo Corporation (K.M., H.K.), Tokyo, Japan
| |
Collapse
|
31
|
Ghonaim HM, Li S, Blagbrough IS. Very long chain N4, N9 -diacyl spermines: non-viral lipopolyamine vectors for efficient plasmid DNA and siRNA delivery. Pharm Res 2008; 26:19-31. [PMID: 18781381 DOI: 10.1007/s11095-008-9705-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2008] [Accepted: 08/06/2008] [Indexed: 01/27/2023]
Abstract
PURPOSE To study the effect of increasing the chain length over C-18 and varying the oxidation level in synthesized N4, N9-diacyl spermines on DNA and siRNA formulation, and then to compare their transfection efficiency in cell lines METHODS The five novel very long chain N4, N9-diacyl polyamines: N4, N9-[diarachidoyl, diarachidonoyl, dieicosenoyl, dierucoyl and dinervonoyl]-1,12-diamino-4,9-diazadodecane were synthesized. The abilities of these novel compounds to condense DNA and to form nanoparticles were studied using ethidium bromide fluorescence quenching and nanoparticle characterization techniques. Transfection efficiency was studied in FEK4 primary skin cells and in an immortalized cancer cell line (HtTA), and compared with the non-liposomal transfection formulation Lipogen, N4, N9-dioleoyl-1,12-diamino-4,9-diazadodecane. Also, the abilities of these compounds to condense siRNA and to form nanoparticles were studied using a RiboGreen intercalation assay and their abilities to deliver siRNA into cells were studied in FEK4 and HtTA cells using fluorescein-labelled Label IT(R) RNAi Delivery Control, a sequenced 21-mer from Mirus. RESULTS We show efficient pEGFP and siRNA formulation and delivery to primary skin and cancer cell lines. CONCLUSIONS Adding two C20 or C22 chains, both mono-cis-unsaturated, N4, N9-dieicosenoyl spermine and N4, N9-dierucoyl spermine, gave efficient siRNA delivery vectors, even in the presence of serum, comparable to TransIT-TKO and with excellent cell viability.
Collapse
Affiliation(s)
- Hassan M Ghonaim
- Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK
| | | | | |
Collapse
|